Advice

following an abbreviated submission:

fluticasone propionate/ formoterol fumarate (Flutiform k-haler®) is accepted for use within NHSScotland.

Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA)] is appropriate:
• For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting β2-agonist or
• For patients already adequately controlled on both ICS and a LABA

Flutiform k-haler is a breath-actuated inhaler that is bioequivalent to Flutiform metered-dose inhaler (pMDI) and costs the same.

Download full details64KB (PDF)

Download

Medicine details

Medicine name:
fluticasone/formoterol (flutiform k-haler)
SMC ID:
SMC2016
Indication:
Indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. • flutiform k-haler) is indicated in adults and adolescents aged 12 years and above.
Pharmaceutical company
Napp Pharmaceuticals Ltd
BNF chapter
Submission type
Abbreviated submission
Status
Accepted
Date advice published:
11 June 2018